Danaher Corporation (DHR) is a global science and technology innovator with a market cap of $147.4 billion. The company operates in the United States, China, and worldwide, providing advanced tools and technologies for healthcare, research, and industrial applications.

Shares of Danaher have declined 26.5% from its 52-week high but have increased 8.1% in the past three months, outperforming the Dow Jones Industrials Average. The stock is down 10.3% YTD and 22.6% over the past year, trading below its 200-day moving average.

Danaher posted Q2 2025 adjusted EPS of $1.80 and revenue of $5.9 billion, exceeding forecasts. The company raised its annual adjusted EPS guidance to $7.70 – $7.80, citing steady bioprocessing demand and signs of recovery in China. Analysts remain bullish about DHR stock, with a consensus rating of “Strong Buy” and a mean price target of $243.33.

Despite underperforming IDEXX Laboratories, Inc., DHR stock has analyst support and positive growth outlooks. The company’s focus on bioprocessing, particularly monoclonal antibodies, is expected to drive long-term growth.

Read more at Yahoo Finance: Is Danaher Stock Underperforming the Dow?